We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved Wilmington Pharmaceuticals’ Metozolv with a risk evaluation and mitigation strategy (REMS) to treat symptoms of acute and recurrent diabetic gastroparesis in adults and for 4-to-12-week therapy of adults with documented symptomatic gastroesophageal reflux disease who have not been helped by conventional therapy.